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One sentence summary:  Lipid-specific CD1a-reactive T cells are enriched in atopic dermatitis skin, 4 
infiltrate after allergen challenge and show increased responses to allergen phospholipase derived 5 
neolipid antigens in the context of filaggrin insufficiency. 6 
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Abstract 33 
Atopic dermatitis is a common pruritic skin disease in which barrier dysfunction and cutaneous 34 
inflammation play a role in pathogenesis. Mechanisms underlying the associated inflammation are not 35 
fully understood, and while CD1a-expressing Langerhans cells are known to be enriched within lesions, 36 
their role in clinical disease pathogenesis has not been studied.  Here we observed that house dust mite 37 
(HDM) generates neolipid antigens for presentation by CD1a to T cells in the blood and skin lesions of 38 
affected individuals.  HDM-responsive CD1a-reactive T cells increased in frequency after birth and 39 
showed rapid effector function, consistent with antigen-driven maturation.  To define the underlying 40 
mechanisms, we analyzed HDM-challenged human skin and observed allergen-derived phospholipase 41 
(PLA2) activity in vivo.  CD1a-reactive T cell activation was dependent on HDM-derived PLA2 and such 42 
cells infiltrated the skin after allergen challenge.  Filaggrin insufficiency is associated with atopic 43 
dermatitis, and we observed that filaggrin inhibits PLA2 activity and inhibits CD1a-reactive PLA2-44 
generated neolipid-specific T cell activity from skin and blood.  The most widely used classification 45 
schemes of hypersensitivity, such as Gell and Coombs are predicated on the idea that non-peptide 46 
stimulants of T cells act as haptens that modify peptides or proteins.   However our results point to a 47 
broader model that does not posit haptenation, but instead shows that HDM proteins generate neolipid 48 
antigens which directly activate T cells.  Specifically, the data identify a pathway of atopic skin 49 
inflammation, in which house dust mite-derived phospholipase A2 generates antigenic neolipids for 50 
presentation to CD1a-reactive T cells, and define PLA2 inhibition as a  function of filaggrin, supporting 51 
PLA2 inhibition as a therapeutic approach. 52 
  53 
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 54 
Introduction 55 
Atopic and allergic diseases affect up to 20-30% of the population and have considerable associated 56 
morbidity, mortality and health economic burden(1).  Atopic dermatitis (AD) is a disease with complex 57 
genetic and environmental susceptibility factors.  Whilst it is known that many loci are involved (2), null 58 
mutations in the gene encoding filaggrin are reproducibly associated with moderate to severe clinical 59 
disease (3, 4). Filaggrin is expressed in keratinocytes and functions in skin barrier, cutaneous pH 60 
regulation, hydration and antimicrobial protection.  As keratinocytes proceed through cornification, 61 
profilaggrin is cleaved into filaggrin monomers which can be incorporated into the lipid envelope and 62 
exposed to the intercellular space.  Thus, a general “outside-in” hypothesis predicts that filaggrin 63 
disruption acts to allow exogenous immune stimuli to enter the skin and activate immune responses (3).  64 
Up to 50% of individuals with homozygous filaggrin null mutations, and up to 5-10% of healthy 65 
European filaggrin null carriers do not have associated atopic dermatitis, suggesting that other 66 
modifying genetic and environmental factors are important, including those that are directly involved in 67 
immune responses, such as FcεR1 and IL-4R genes (5).  Indeed many cytokines modify filaggrin and anti-68 
microbial peptide expression (6-10), and anti-IL-4R therapy has shown significant efficacy in atopic 69 
dermatitis treatment (11).  Separately, there is convincing evidence that antigen-specific reactivity to 70 
environmental challenge has a role in the pathogenesis of atopic dermatitis.  For example, the pathology 71 
of atopic dermatitis shares many features with classic delayed-type hypersensitivity, including epidermal 72 
oedema and a dominant T cell inflammatory infiltrate.  Approximately 80% of individuals with atopic 73 
dermatitis have elevated serum IgE which recognize proteins derived from one or more ubiquitous 74 
environmental allergens, including house dust mite (HDM), animal dander, pollens and fungal allergens 75 
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(eg Aspergillus spp) (12).  Allergen peptide-specific type 2 cytokine-producing T cells have been 76 
documented in many studies to be present in the peripheral blood of affected individuals (13-17).   77 
Recently, type 2 innate lymphoid cells (ILC2) have been shown to be enriched in lesional atopic 78 
dermatitis skin and to infiltrate after HDM challenge (18).  The production of type 2 cytokines by ILC2 is 79 
enhanced by PGD2, IL-33, IL-25 and TSLP and increases in the setting of reduced E-cadherin, believed to 80 
be mediated through loss of KLRG1 inhibitory signals (18, 19).  Overall these data suggest that type 2 81 
cytokine production by a number of cell types including T cells and ILC2 can compound barrier 82 
insufficiency and contribute to inflammation, supporting the alternate “inside-out” hypothesis. However 83 
there remains considerable debate about the relative roles of barrier function and cutaneous 84 
inflammation in atopic dermatitis pathogenesis.  This is an important question in order to define how 85 
best to target future therapeutic strategies. 86 
CD1a is an MHC-like antigen presenting molecule and is highly expressed by Langerhans cells of the 87 
epidermis and by a subset of dermal dendritic cells, as well as subsets of dendritic cell populations at 88 
other sites, including lung, gut and genital mucosa (20-24).  CD1a presents self (25) and foreign (26) 89 
lipids to T cells, so the abundant expression of CD1a on epidermal Langerhans cells would be compatible 90 
with the detection of skin barrier compromise through binding endogenous or exogenous lipids for 91 
presentation to CD1a-reactive T cells (27). Indeed, lesional cutaneous atopic tissue carries an altered 92 
lipid profile (28-32) that is a candidate for influencing CD1a-mediated T cell activation, and CD1a+ cells 93 
are enriched within atopic dermatitis lesions (33).  Recently studies show that CD1a-reactive T cells 94 
circulate at far higher frequencies than previously considered and can infiltrate normal human skin (27, 95 
34, 35).  CD1a autoreactive T cells produce cytokines that contribute to skin disease, like IL-22 and 96 
interferon-(27), and whereas other CD1 proteins use complex intracellular processing pathways, CD1a 97 
directly captures and displays extracellular lipids with few specialized loading requirements (36). (37-98 
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40)(41)(36)(27)(35)(40)(42, 43)Together, the natural accumulation of autoantigens, CD1a proteins and 99 
CD1a autoreactive T cells point to a natural organ-specific function in skin, but insights into clinical 100 
diseases are limited.  Recently, we have identified that fatty acids generated by phospholipase activity in 101 
wasp and bee venom can be recognized by CD1a-reactive T cells (44). Further, pollen-derived 102 
phospholipids have been implicated as targets for lipid-specific T cells, including CD1d and CD1a reactive 103 
T cell clones (45).  Based on these findings, we considered that CD1a might play a role in atopic 104 
dermatitis. Specifically, given the enrichment of CD1a-expressing cells and altered lipids in lesional 105 
atopic dermatitis skin, we sought to test the hypothesis that CD1a-reactive lipid-specific T cells 106 
contribute to the human response to dust mites and atopic dermatitis. 107 
108 
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Results 109 
House dust mite is recognized by CD1a-reactive T cells 110 
To determine whether HDM could be recognized by CD1a-reactive T cells isolated ex vivo from 111 
individuals with atopic dermatitis, we incubated polyclonal T cells with K562 target cells transfected with 112 
CD1a (K562-CD1a) in the presence or absence of whole HDM extract. K562 cells are HLAlow and thereby 113 
largely bypass alloreactivity and allow parallel testing with T cells from many unrelated donors under 114 
equivalent conditions.  We measured both type 1 and type 2 cytokine production, as both have been 115 
implicated in disease pathogenesis (46-49).  As seen previously (27, 35, 44), we observed a trace 116 
response to K562 cells at a rate of ~1 in 10,000.  Above this trace background rate, we detected large 117 
increments in IFN response to K562-CD1a cells, which likely reflects the presence and activation of 118 
autoreactive T cells recognising CD1a and endogenous K562-derived lipids (Figure 1A, donor R9500).  119 
Further, we noted significantly (P<0.0001) increased activation by K562-CD1a target cells when pulsed 120 
overnight with house dust mite extract.  Importantly, no response above background was seen in 121 
response to control APCs transfected with vector alone, demonstrating that the response to dust mite 122 
extract is CD1a-mediated.  Polyclonal T cells from the same donor also produced GM-CSF and IL-13 in 123 
response to dust mite products with a similar pattern, except that the rate of cellular response was 124 
particularly high for GM-CSF, reaching to more than 0.5 percent of all T cells in some cases  (Figure 1B). 125 
The response was inhibited by an anti-CD1a antibody, but not by isotype control (Figure 1C). Responses 126 
were in clinically and physiologically relevant dose ranges, as titration to 0.07g/ml HDM extract (Figure 127 
1D), which is approximately 0.3% of doses administered in vivo during maintenance immunotherapy (up 128 
to 21g) (50), caused detectable T cell responses.    129 
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K562-CD1a represent an engineered APC that has the advantage of use with any donor to test the inter-130 
donor reproducibility of the response in a defined system, but these transformed cells might not mimic 131 
the antigens or co-stimulatory processes of the two native CD1a+ APCs:  myeloid dendritic cells and 132 
Langerhans cells (LC). We differentiated monocytes with GM-CSF and IL-4 to produce monocyte-derived 133 
myeloid dendritic cells (mDCs) and also activated cells in vitro with cytokines to mimic LCs (in vitro LCs, 134 
supplementary figure 1) (51-54).  Similar to prior studies that compared K562 cells, mDCs and LC-like 135 
cells side by side, we found that both mDCs and LC-like cells mediated the HDM response of polyclonal 136 
autologous T cells in a CD1a-reactive manner (Figure 1E).  Overall, our data show house dust mite-137 
responsive CD1a-reactive T cells exist in the peripheral blood of healthy individuals at high frequencies 138 
and produce IFN, GM-CSF and IL-13 in response to HDM challenge at relevant doses. 139 
 140 
HDM-responsive CD1a-reactive T cells are enriched in blood and skin of atopic dermatitis patients  141 
Next we examined responses to house dust mites in a larger cohort of healthy adult donors and 142 
individuals with atopic dermatitis, and compared these to responses in cord blood of neonates, which 143 
represent a control for naïve polyclonal T cells.   We observed significantly higher CD1a-reactive ex vivo T 144 
cell IFN responses to HDM in individuals with atopic dermatitis compared to healthy non-atopic 145 
controls (Figure 2A).  The frequencies of IFN producing cells were significantly (P<0.0001) higher in 146 
adult donors than in cord blood samples, consistent with an acquired antigen-driven T cell expansion 147 
(Figure 2A).  In addition, the production of IL-13 by CD1a-reactive T cells was also significantly (P<0.001) 148 
elevated ex vivo, confirming type 1 and type 2 cytokine induction (Figure 2B).  Using dual-color ELISpot, 149 
we showed while the majority of the type 1 and type 2 cytokine-producing cells are unique subsets, a 150 
mean of 7% of CD1a-reactive HDM-responsive T cells could produce both IFN and IL-13 (Supplementary 151 
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Figure 2A).  However we do not observe an increase in the IFN or IL-13 producing HDM-responsive 152 
CD1a-reactive T cells in patients with psoriasis (Supplementary Figure 2B).  Given the association 153 
between filaggrin null mutations and moderate-severe atopic dermatitis, we genotyped the patients and 154 
controls for the two most common mutations found in Europeans (2282del4 and R501X). Frequencies of 155 
the HDM-responsive CD1a-reactive T cells were significantly increased in those individuals with filaggrin 156 
null mutations compared to those with wild-type filaggrin (contingency chi-squared 4.38, P<0.05, 157 
Supplementary Figure 3A). Furthermore, the percentage of IL-13 producing CD1a-reactive HDM-158 
responsive T cells significantly correlated with disease severity (r2=0.445, P<0.001) and there was a 159 
significant correlation between fold increase in HDM-responsive T cells and total IgE (r2=0.588, P<0.05) 160 
and HDM-specific IgE (r2=0.502, P<0.05). Overall, these data showed that HDM-responsive, CD1a-161 
reactive T cells increase in frequency in adults, show effector function, and are enriched in the 162 
circulation of patients with atopic dermatitis.  163 
To examine whether HDM-responsive cells were also present within skin from patients with atopic 164 
dermatitis and healthy controls, we used skin suction blisters to isolate T cells from skin.  This method 165 
uses low pressure, sustained suction for 60 minutes to produce extracellular blister fluids that are 166 
captured for immunological and biochemical analysis, and can be performed before or after antigen 167 
challenge (18).  The approach has the advantage over conventional skin biopsies in that cells and fluid 168 
can be aspirated from the skin and used in functional assays, without the need for prolonged processing 169 
with potentially confounding treatments, such as dispase and collagenase.  We observed that HDM-170 
responsive CD1a-reactive T cells are present in skin and produce IFN, GM-CSF and IL-13 (Figure 2C and 171 
2D).  Furthermore the IL-13 producing T cells are enriched in the skin of patients with atopic dermatitis 172 
compared to skin of healthy controls (Figure 2E) and the frequency correlated with SCORAD disease 173 
severity (r2=0.67, P<0.01), showing that T cell infiltration into atopic dermatitis lesions correlates both 174 
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with disease outcome and type 2 cytokine production in humans ex vivo. To investigate the CD1a-175 
reactive immune response in vivo, we challenged the skin intra-epidermally with 0.7g HDM extract and 176 
assessed skin infiltration of HDM-responsive T cells at 24 hrs.  We chose a dose at <5% of the amount 177 
administered during the maintenance phase of subcutaneous immunotherapeutic approaches (typically 178 
up to 21g) to assure safety and attempt to mimic low dose exposures (50).   We noted skin infiltration 179 
of IFN, GM-CSF and IL-13-producing HDM-responsive T cells at 24 hours suggesting that the cells 180 
infiltrate early and may therefore contribute to the ensuing inflammation (Figure 3A and Supplementary 181 
Figure 3B).  Furthermore in those with atopic dermatitis, we observed significantly greater infiltration of 182 
IFN-producing HDM-responsive CD1a-reactive T cells after HDM challenge than in healthy controls 183 
(Figure 3B, left panel).  In contrast, there was no enrichment for varicella zoster virus-specific T cells in 184 
the skin after HDM challenge, suggesting that the enrichment is specific to HDM-responsive T cells 185 
(Figure 3B, right panel). 186 
As described above, type 2 cytokines can influence filaggrin and anti-microbial peptide expression in the 187 
skin.  We investigated the type 2 cytokine content of skin blisters derived from patients with atopic 188 
dermatitis and healthy controls with sampling at non-lesional skin, and after HDM challenge.  These 189 
studies showed that after HDM challenge of non-lesional skin in atopic dermatitis patients, the 190 
concentrations of type 2 cytokines IL-4, IL-5, IL-13 and GM-CSF within skin blister fluid were significantly 191 
increased compared to healthy donors (Figure 3C).   192 
Overall these data demonstrate that HDM-responsive CD1a-reactive T cells are present in the blood and 193 
skin of healthy donors, but are enriched in the blood and skin of patients with atopic dermatitis. 194 
Furthermore, after intra-epidermal HDM allergen challenge, the T cells infiltrate rapidly and associate 195 
with the production of type 2 cytokines in vivo.   196 
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 197 
HDM-responsive CD1a-reactive T cell responses are explained by PLA2 activity 198 
To identify the antigenic substance in house dust mites, we first treated HDM extract with chloroform 199 
and methanol to recover protein-enriched aqueous and lipid-enriched organic fractions before testing 200 
the differential capacity to sensitise CD1a-expressing K562 cells for recognition by T cells and 201 
unexpectedly observed responses to the protein-enriched fractions rather than the lipid-enriched 202 
fractions (Figure 4A).  This counterintuitive result could be explained by other experiments that were 203 
recently reported (44), which showed that the origin of CD1a mediated responses to bee venom also 204 
derived from proteinaceous fractions of venom, and were identified as phospholipases.  Phospholipases 205 
generated antigenic free fatty acids or lysolipids from non-antigenic phosphodiacylglycerols.  We posited 206 
that a parallel mechanism existed here and tested it by examining PLA2 biochemical activity in vivo and 207 
in vitro using colorimetric thiol detection after release from diheptanoyl thio-PC substrate.  Interestingly 208 
there was PLA2 activity measured in all skin blister samples, which significantly increased after HDM 209 
challenge (Figure 4B).  Furthermore, HDM-induced PLA2 activity within skin blister fluid was significantly 210 
inhibited in the presence of the known PLA2 inhibitor manoalide (Figure 4C). We next demonstrated 211 
that HDM extract contains PLA2 activity in vitro, which could be inhibited by manoalide and heat 212 
inactivation (Figure 4D).   213 
Heat inactivation of house dust mite extract or treatment with the PLA2 inhibitor manoalide abrogated 214 
the CD1a-dependent recognition of HDM-pulsed K562-CD1a cells, but did not affect the autoreactive T 215 
cell response (Figure 5A) or viral-specific T cell responses (Supplementary figure 4).  Together these 216 
suggest that the CD1a-reactive HDM responses are secondary to PLA2, most likely through generation of 217 
neolipid antigens.  We next sought to determine if skin-derived HDM-responsive CD1a-reactive T cells 218 
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were also dependent on PLA2 activity.  Figure 5B shows that IFN and GM-CSF production by skin T cells 219 
derived ex vivo following intra-epidermal HDM challenge to human skin are also inhibited by heat 220 
inactivation of the HDM or by treatment with manoalide.  Furthermore, we show that skin HDM-221 
responsive CD1a-reactive T cells are also able to respond to purified bee venom PLA2 (44), another 222 
recognized PLA2-containing allergen (Figure 5C).  This result points to shared pathways of skin 223 
inflammation despite different depths of natural antigen delivery by venom and dust mites.  Overall, 224 
HDM-derived PLA2 has the capacity to generate neolipid antigens for recognition by CD1a-reactive T 225 
cells.  The lack of response with the lipid fraction of HDM extract suggests that skin derived lipid sources 226 
represent the principle substrates of HDM PLA2.   227 
 228 
Filaggrin inhibits HDM PLA2 and CD1a-reactive T cell responses 229 
Given that filaggrin insufficiency is associated with moderate-severe atopic dermatitis and that we have 230 
shown an association between CD1a-reactive T cell responses to HDM and filaggrin null mutations, we 231 
designed experiments to test the hypothesis that filaggrin directly contributes to the CD1a-reactive T cell 232 
response. We investigated the possibility that filaggrin itself can directly inhibit PLA2 activity, and 233 
observed that filaggrin monomers efficiently inhibited HDM PLA2 biochemical activity at levels 234 
equivalent to those present in the stratum corneum in vivo (55) (Figure 6A).  Furthermore recombinant 235 
filaggrin monomers inhibited the PLA2 activity observed within skin blister fluid after intra-epidermal 236 
challenge with HDM (Figure 6B).  We next investigated whether filaggrin could inhibit cytokine 237 
production by HDM-responsive CD1a-reactive T cells and showed that recombinant filaggrin monomers 238 
significantly inhibited IFN, IL13 and GM-CSF production by T cells derived from blood ex vivo (Figure 239 
6C).  However we did not show filaggrin-inhibition of autoreactive T cells or viral specific T cells 240 
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(Supplementary Figure 4), ruling out a non-specific toxic effect of the filaggrin on T cells.  Lastly we 241 
demonstrated that the filaggrin monomers inhibited GM-CSF production by T cells derived ex vivo from 242 
skin after HDM skin challenge (Figure 6D).   These data suggest that filaggrin may provide barrier 243 
function status signals to the innate and adaptive immune responses through effects on PLA2. 244 
 245 
  246 
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Discussion 247 
Although CD1a protein is expressed at constitutively and at extraordinarily high density on Langerhans 248 
cells that form a broad network in the epidermis, and CD1a autoreactive T cells normally enter the skin 249 
in large numbers, there are no studies addressing the specific role of CD1a-reactive T cells in human skin 250 
disease.  Here we have shown that HDM generates CD1a ligands for recognition by T cells.  Such HDM-251 
responsive CD1a-reactive T cells are enriched in the blood and skin of individuals with atopic dermatitis 252 
and correlate with IgE and disease severity, and are significantly elevated in the presence of filaggrin null 253 
mutations.  Furthermore the CD1a-reactive T cells infiltrate the skin 24 hours after HDM challenge, 254 
which associates with type 2 cytokine production and phospholipase (PLA2) activity in vivo.  We showed 255 
that the HDM responsiveness of CD1a-reactive T cells was explained by the presence of PLA2 activity 256 
within HDM, and that the PLA2 activity could be inhibited by recombinant filaggrin.  These studies 257 
identify a pathway of atopic skin inflammation, in which neolipid antigens are generated from the skin 258 
by HDM-derived PLA2 for CD1a-mediated presentation to T cells.  Loss of filaggrin inhibition of HDM 259 
PLA2 may provide neolipid signals to CD1a-reactive T cells that barrier compromise has occurred, with 260 
potential inflammatory sequelae. 261 
All previous studies investigating the potential role of antigen-specific T cells in the pathogenesis of 262 
atopic dermatitis have focussed on peptide-specific responses that are restricted through HLA class I and 263 
class II  (15, 16).  The current study implicates HDM PLA2 processed skin lipids as a broad antigen class 264 
that should be added as potential candidate antigens recognized by T cells and relevant to clinical atopic 265 
disease.  Langerhans cells are enriched in atopic dermatitis lesions (33), where there is a dysregulated 266 
lipid profile (28-32) consistent with a potential role of such cells in presenting lipid to T cells. It is of 267 
interest that many known allergens are lipid-binding proteins which may become targets of peptide-268 
specific T cell and IgE responses when conjugated to their lipid cargo.  Langerin is a C-type lectin 269 
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expressed by subsets of dendritic cells including Langerhans cells, and is thought to contribute to lipid-270 
loading of CD1a; it is of interest that langerin has recently been identified in a Genome-Wide Association 271 
Study of atopic dermatitis (56). The widely taught Gell and Coombs classification system summarizes a 272 
large literature that T cells play a functional role in Type IV hypersensitivity responses in humans, even 273 
though the immunogens are often not typical peptide antigens for T cells (57).  The mechanisms by 274 
which non-peptide antigens lead to T cell-mediated response can involve haptenization of proteins (58), 275 
but it is unknown if this is generally true.  In most cases the mechanisms for T cell stimulation by small 276 
molecules and other non-peptide antigens are unclear.  The CD1 system is a particularly attractive 277 
candidate to mediate response to non-peptide immunogens, as it evolved to present lipids and small 278 
molecules to T cells (59, 60).  Through its expression on Langerhans cells and a subset of dermal 279 
dendritic cells, CD1a protein is well placed to sample non-peptide antigens that are exposed to the skin. 280 
The results presented here suggest a broader model of Gell and Coombs hypersensitivity where neolipid 281 
recognition by CD1a-reactive T cells is associated with clinical atopic disease.  There may therefore exist 282 
a multi-hit process where a CD1a-reactive response may be part of a barrier sensing system that if 283 
activated, can induce other adaptive immune responses and cutaneous inflammation.  This is germane 284 
to animal models, in which cutaneous stress responses enhance sensitization (61).  The data may also 285 
provide insights to why only certain environmental challenges are particularly allergenic.  Such pro-286 
allergenic sources, including house dust mite, may preferentially activate a barrier distress system 287 
through generation of inflammatory lipids, leading to immune responses to co-existent proteins and 288 
subsequent clinical disease.  These processes may be compounded by genetically-determined or 289 
acquired filaggrin insufficiency. 290 
CD1a protein is a member of the group 1 CD1 family, along with CD1b, CD1c and CD1e.  The group 1 291 
family is not present in mice, yet each member has a distinct cytoplasmic domain, intracellular 292 
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trafficking and tissue distribution which suggests functional specialization (59).  CD1a-autoreactive T 293 
cells were found to infiltrate human skin where they could recognize skin derived self-lipids, including 294 
fatty acids, presented by primary CD1a-expressing antigen presenting cells (35).  We have recently 295 
shown that wasp and bee venom derived phospholipase can generate self-lipids for presentation by 296 
CD1a protein suggesting shared pathways of skin inflammation, albeit with differing clinical phenotypes 297 
dependent on depth of antigen delivery (44). Furthermore phospholipase activity is required for 298 
generation of CD1d-restricted NKT cell ligands in a model of hepatitis virus infection (62, 63), and thymic 299 
PLA contributes to the control of NKT cell selection (64). It is therefore possible that other CD1s may 300 
present shared antigens and contribute to inflammatory skin disease in the presence or absence of CD1a 301 
deficiency (65).  However no studies have linked CD1a to biological processes relevant in human disease. 302 
Secretory phospholipase A2 cleaves phospholipid to lysophospholipid and the sn-2 acyl chain, and while 303 
mechanisms have not been clear, it has long been implicated as having a role in atopic disease (66-73).  304 
Although PLAs are likely to have many roles, here we show that PLA-derived lipid products are 305 
presented by CD1a for recognition by T cells in the skin.  Indeed, we also show that recombinant 306 
filaggrin can inhibit the PLA2 activity of HDM and can inhibit the generation of CD1a neolipid ligands for 307 
presentation to T cells.  This is a hitherto unappreciated function of filaggrin, which may help link the 308 
presence of filaggrin insufficiency to cutaneous inflammation.   The data also provide a potential 309 
resolution to the seemingly contrasting “inside-out” and “outside-in” hypotheses of atopic dermatitis, 310 
where instead of two independent possibilities, filaggrin can act in both a barrier function/hydration 311 
capacity and also as a direct inhibitor of cutaneous lipid-specific immune responses.  However clinical 312 
disease may depend on a multi-hit process where filaggrin insufficiency combines with modulations in 313 
innate and adaptive immune responses.  By inhibiting down-stream innate and T cell effector functions, 314 
for example through anti-IL-4R, acquired down-regulation of filaggrin may be reversed, leading to 315 
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enhanced filaggrin inhibition of PLA2, and less barrier distress signals to CD1a-reactive T cells.  20-40% of 316 
individuals with moderate-severe atopic dermatitis have filaggrin null mutations, yet acquired filaggrin 317 
insufficiency and barrier impairment are common (3, 9).  This supports the findings presented herein in 318 
which specific aspects related to the downstream immunological events are also important in 319 
contributing to the filaggrin insufficiency and compounded atopic cutaneous inflammation through a 320 
multi-hit model of disease pathogenesis (9, 74).  The data further substantiate the pursuit of therapeutic 321 
strategies that modulate relevant immune responses. 322 
Given that PLA2 generation of CD1a ligands has now been shown to be present in three allergens of 323 
relevance to humans (44), namely wasp venom, bee venom and HDM, the data suggest that this is part 324 
of a broader hypersensitivity system.  Indeed phospholipases are known to be present in many other 325 
allergens including pollens and fungal allergens (75, 76) and therefore activation of this pathway may 326 
facilitate the allergenic process.  By producing type 2 cytokines, CD1a-reactive lipid-specific T cells may 327 
lead to down-regulation of filaggrin and anti-microbial peptide expression and thus compound physical 328 
and antimicrobial barrier dysfunction.  Furthermore they may license skin dendritic cells to amplify 329 
peptide-specific Th2 responses and subsequent IgE generation.  For example, it is of interest that GM-330 
CSF and IL-4 are routinely used to mature monocytes towards cells with CD1 and class I/II antigen 331 
presenting capacity. If CD1a-reactive responses do contribute to initiation of the allergic process, then 332 
we might predict that allergens delivered to anatomical sites that do not contain antigen presenting cells 333 
with high levels of CD1a protein would lead to differing systemic responses.  This is indeed the case as 334 
wasp venom, bee venom and grass pollen subcutaneous immunotherapy are all known to be highly 335 
effective (77, 78). In contrast to the epidermis and dermis, subcutaneous tissue has few CD1a-expressing 336 
cells.  The findings therefore have potential therapeutic implications. It is of interest that corticosteroids 337 
are known to inhibit PLA (79), and it may be that in the skin, this is an important mechanism for 338 
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controlling CD1a-reactive T cell activity. The development of PLA inhibitors that target individual 339 
relevant allergen PLAs may enhance treatment efficacy whilst reducing side effects of broad host PLA 340 
inhibition seen with current corticosteroids. 341 
While skin suction blisters offer access to human skin fluid and cells directly ex vivo without the need for 342 
further processing, they do add a potential limitation of the study.  They are time consuming for donors, 343 
and so participant numbers become limiting.  Furthermore skin suction blisters inevitably introduce 344 
physical trauma to the skin and so it is important to use control comparisons of unchallenged or non-345 
lesional skin when examining challenged or lesional skin respectively.  The current study is a cross-346 
sectional analysis of affected individuals, and it will be important to validate the findings in other cross-347 
sectional cohorts and to examine changes longitudinally.  Lastly, although it is recognized that 348 
translational work has to pass through stages involving human subjects at some point during 349 
development, it can be difficult to prove causality in humans.  Human skin antigenic challenge does offer 350 
temporal associations with clinical and immunological findings, lending support of causality, but CD1a 351 
transgenic models and human skin grafts in immunodeficient models may offer further evidence in the 352 
future. 353 
In conclusion, we identify a pathway of human skin inflammation where HDM-derived PLA2 generates 354 
neolipid antigens for presentation to CD1a-reactive T cells.  By also defining a function of filaggrin in 355 
inhibiting PLA2, we are able to potentially unify the conflicting “outside-in” and “inside-out” hypotheses 356 
of atopic dermatitis.  The data would support therapeutic approaches to inhibit allergen-derived PLA2 357 
activity, together with treatments that target the downstream immunological effector pathways. 358 
 359 
  360 
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Materials and Methods 365 
Study design. The study was a laboratory analysis of human blood and skin T cell responses designed to 366 
test the hypothesis that CD1a-reactive lipid-specific T cells contribute to the human response to dust 367 
mites and atopic dermatitis.  Atopic dermatitis was diagnosed according to the UK refinements of the 368 
Hanifin and Rajka diagnostic criteria, and adult participants were only excluded if on systemic 369 
immunosuppression or topical calcineurin inhibitors.  Participants were recruited sequentially; blinding 370 
and randomization were not required as there was no intervention.  Sample size was determined based 371 
on previous studies of CD1a-reactive T cell response frequencies in humans (80).  All experiments were 372 
replicated as presented in the figure legends. 373 
 374 
Isolation of human T-cells.  Peripheral blood mononuclear cells (PBMC) were isolated from healthy adult 375 
donors and atopic dermatitis patients under local ethics approval (09/H0606/71). Atopic dermatitis was 376 
diagnosed using the UK refinements of the Hanifin and Rajka diagnostic criteria and disease severity was 377 
assessed using SCORAD.  Donors aged 18-67 were recruited with disease severity SCORAD range 5-70.  378 
Patients were using topical corticosteroids, but were not on systemic immunosuppression nor topical 379 
calcineurin inhibitors.  Adult (18-67 years) patients were recruited with moderate severity psoriasis who 380 
were not on systemic therapy.  T-cells were purified from ficollized peripheral blood mononuclear cells 381 
using CD3 MACs beads (Miltenyi Biotec). CD1a reactivity was assessed by IFN- ELISPOT (Mabtech AB). 382 
ELISpot plates (Millipore Corp) were coated with anti-IFN-γ, anti-GM-CSF or anti-IL-13 antibody 383 
overnight (Mabtech AB). K562 cells were pulsed with HDM extract (7g/ml unless otherwise stated) or 384 
1g/ml purified bee venom PLAs (Sigma) overnight, and were then washed and re-suspended in R5* 385 
(RPMI supplemented with 2mM L-glutamine, 100 IU/ml penicillin and 100 μg/ml streptomycin plus 5% 386 
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human serum). The plates were washed six times with RPMI and blocked for 1h with RPMI 387 
supplemented with 2 mM L-glutamine, 100 IU/ml penicillin and 100  μg/ml streptomycin plus 10% 388 
human serum (R10*).  20-50,000 T-cells were added per well to which 10-25,000 K562 or primary cells 389 
were added. Wells were set-up in duplicate or triplicate.  Phorbol myristate acetate 10 ng/ml and 390 
Ionomycin 500 ng/ml was included as a positive control, and T-cells alone in the absence of K562 was 391 
included as a negative control.  After overnight incubation at 37°C and 5% CO2, plates were washed x6 392 
in PBS-Tween 0.05% and incubated with 1 μg/ml of biotin-linked anti-IFN-γ, anti-GM-CSF or anti-IL-13 393 
monoclonal antibody (Mabtech AB) for 2 h.  After washing x 6 in PBS-Tween 0.05%, the plates were 394 
incubated for a further 1 hour with streptavidin-alkaline phosphatase (Mabtech AB).  Spots were 395 
visualized using an alkaline phosphatase conjugate substrate kit (Biorad) and enumerated using an 396 
automated ELISpot reader (Autimmun Diagnostika gmbh ELISpot Reader Classic). In some experiments 397 
10 g/mL anti-CD1a blocking antibody (OKT-6), or 10 g/mL IgG1 isotype control (P3), or 10 M 398 
manoalide, an inhibitor of PLA2 that acts by covalently modifying lysine residues (Enzo Life Sciences), or 399 
0.5 g/mL Filaggrin monomers were added at to K562 or primary cells before addition of T cells. The 400 
frequency of the specific T-cell response was determined in polyclonal T-cell cultures derived from 401 
healthy controls (HC) and atopic dermatitis patients (AD) by calculating the mean number of spots/well 402 
in the K562-CD1a-HDM pulsed ELISpot wells and subtracting the mean number of spots/well in the 403 
K562-EV-HDM pulsed ELISpot wells.  The frequency of the CD1a-autoreactive IFNγ T-cell response was 404 
determined by calculating the mean number of spots/well in the K562-CD1a unpulsed ELISpot wells and 405 
subtracting the mean number of spots/well in the K562-EV unpulsed ELISpot wells. For the Varicella 406 
zoster virus (VZV) T-cell responses, T-cells were washed and re-suspended in R5* and 1 vial (103.3 407 
PFU/0.5ml) of Varilrix (live VZV vaccine, GlaxoSmithKline) was resuspended in 500l R5*. 50l of the 408 
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reconstituted virus was incubated with 100,000 T-cells overnight.  50l R5* was incubated with 100,000 409 
T-cells overnight as a negative control.  IFN and IL13 production were determined by ELISpot. 410 
Viral-specific T cell lines.  We generated HLA-A*0201-restricted GILGFVFTL (influenza A matrix), 411 
NLVPMVATV (CMV pp65) and GLCTLVAML (EBV BMLF1)-specific T cells by sorting from peripheral blood 412 
mononuclear cells ex vivo with relevant class I tetrameric complexes with maintenance as previously 413 
described (81).  Cells were cultured in R10 at 2 × 106 cells per well in a 24-well Costar plate. IL-2 was 414 
added to a final concentration of 100 U/ml on day 3. The cultures were restimulated after 14 d using 415 
HLA-A*0201-positive BCLs pulsed with the appropriate peptides. For the functional assays, cells were 416 
pulsed with 200 ng/ml peptide and incubated with 10 M manoalide, 0.5g/ml filaggrin monomers or 417 
0.5 g/mL Sumo recombinant protein control before IFN ELISpot as above. ELISpots were performed 418 
using a ratio of 40,000 : APC cells (JY) : 5,000 T-cells.Isolation and generation of human APCs. We 419 
generated autologous mDC-DCS using CD14+ monocytes. CD14+ human cells were isolated using MACS 420 
cell separation (Miltenyi Biotec Inc) according to the supplier’s instructions. These cells were then 421 
differentiated in medium containing 50ng/ml GM-CSF and 1000iu/ml IL-4.  After 4 days, CD1a expression 422 
was confirmed by Flow Cytometry, and the differentiated mDCS were used as antigen presenting cells 423 
for the ELISpot assay.  The in vitro mDCs were incubated with 10 µg/ml anti-HLA-ABC and anti-HLA-DR 424 
blocking antibodies (W6/32 and L243 respectively) for one hour prior to co-culture with T-cells, in order 425 
to minimize HLA-restricted responses.  We generated autologous LC-like cells in vitro using CD14+ 426 
monocytes. CD14+ human cells were isolated using MACS cell separation (Miltenyi Biotec Inc) according 427 
to the suppliers’ instructions. Briefly, such in vitro LC-like cells were prepared as previously described 428 
(51, 52) from CD14+ cells, which were cultured in 6-well plates in complete medium in the presence of 429 
IL-4 (250 ng/ml; PeproTech), GM-CSF (100 ng/ml) and TGF-1 (10 ng/ml; PeproTech).  At days 2 and 4, 430 
cultures were re-plated in the presence of the above cytokines to generate cells which were 24.9-26.5% 431 
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CD1a+CD207+. The in vitro LC-like cells were incubated with 10 µg/ml anti-HLA-ABC and anti-HLA-DR 432 
blocking antibodies (W6/32 and L243 respectively) for one hour prior to co-culture with T-cells, in order 433 
to minimize HLA-restricted responses.  434 
HDM lipid extraction. HDM lipids were extracted with chloroform, methanol and water using a modified 435 
Bligh-Dyer method (82).  Briefly, HDM extract was resuspended in a solution of (4:2:1) 436 
methanol:chloroform:sample and vortexed before being heated for 30 minutes at 37-40°C.  2 volumes 437 
of chloroform and 3 volumes of water were added and the sample was vortexed again and centrifuged 438 
at 2-3000 RPM for 5 minutes resulting in separation of the aqueous and organic phases.  This process 439 
was repeated twice on the aqueous phase to achieve maximal yield.  The organic phase was then 440 
aspirated, dried by dessication, weighed and dissolved in 0.5% PBS-Tween.  The aqueous phase was 441 
aspirated, centrifuged at 3000 RPM for 5 minutes and protein-enriched precipitates were resuspended 442 
in sterile PBS and concentration determined by Nanodrop. 443 
Blister fluids. Health donor epidermis was injected with 0.7 g of Dermatophagoides pteronissimus HDM 444 
extract (ALK) or saline. After 30 minutes, suction was applied to the skin at 200 mmHg for 1h, which 445 
induces a split between the epidermis and dermis (18).  Blister fluid was isolated by needle aspiration at 446 
24 hours and the cells were separated by centrifugation. The blister fluid phase was immediately stored 447 
at -20oC. Cytokines were measured by multiplex bead array.   Blister derived T cells were FACS sorted 448 
and expanded using the rapid expansion method.  Specifically, T-cells were plated out at 100-150 449 
cells/well into T-cell media in a round-bottom 96-well plate and 50ng/ml of anti-CD3 (OKT3) antibody 450 
and irradiated PBMC and EBV transformed B-cells at 150-200,000 cells/well and 40,000 cells/well 451 
respectively were added.  Blister T-cells were examined and split regularly and on expansion were 452 
maintained at a density of approximately 0.5-1 million cells/ml. 453 
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PLA2 biochemical activity experiments. PLA2 activity in HDM and blister fluids were detected using site 454 
specific substrate kit (Cayman Chemicals), according to manufacturers’ instructions. In a flat-bottom 96-455 
well plate, 10 µl (0.7 g ) HDM extract (ALK) or blister fluid plus 5 µl assay buffer and 10 µl DTNB, were 456 
incubated at RT with 200 µl  substrate solution (diheptanoyl thio-PC). For inhibitor/filaggrin studies, 457 
HDM/blister fluid was incubated with the appropriate concentration of manoalide or filaggrin for 30 458 
minutes at RT prior to plating out.  In the presence of PLA2, cleavage of the substrate at the sn-2 459 
position results in release of the thiol group, which reacts with DTNB to produce a colored precipitate.  460 
This is measured with a spectrophotometer over time (415nm) to give a measure of PLA2 activity (Bio-461 
Rad iMark™ Microplate Reader). 462 
 463 
Filaggrin synthesis. The expression plasmid was constructed using a sequence- and ligation-independent 464 
cloning (SLIC) method (83). Nucleotide sequence encoding 7th filaggrin repeat domain was cloned into 465 
pET28 vector using  BamHI i XhoI restrictions sites. The construct contains N-terminal His6-tagged SUMO 466 
protein sequence which can be enzymatically cleaved by SUMO protease. The construct was 467 
transformed into E. coli BL21-CodonPlus-RIL and propagated overnight in LB liquid media containing 468 
kanamycin (50 µg/ml) and chloramphenicol (37.5 µg/ml) at 37°C. The bacterial cultures were diluted 469 
1:50 in autoinduction media (Formedium AIM- Super Broth) supplemented with kanamycin and 470 
chloramphenicol and incubated for 48 h at 18°C with shaking. The cells were harvested by centrifugation 471 
(10 min, 5000 × g, 4°C). The bacteria pellet was mixed with lysis buffer (10 mM Tris pH 8, 150 mM NaCl, 472 
10 mM imidazole) supplemented with  protease inhibitors cocktail and lysed by sonication. The cell 473 
lysate was clarified by centrifugation (45 min, 70000 × g, 4°C). The following described purification 474 
procedure was performed on an ÄKTA™xpress chromatography system. The supernatant after 475 
centrifugation was loaded on Ni–NTA Agarose column (Qiagen). Unbound material was washed from the 476 
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column with lysis buffer. Enriched proteins were subjected to on-column cleave by SUMO protease (20 477 
g protease for 5 ml resin) in elution buffer (10 mM Tris pH 8, 150 mM NaCl, 300 mM imidazole) for 8 h 478 
at 10°C. Realised protein was further purified by combinations of desalting and Ni-NTA Agarose columns 479 
equilibrated with the lysis buffer. Flow though fractions containing the purified protein were collected 480 
and automatically loaded into a pre-equilibrated column with buffer (10mM Tris pH 8, 150mM NaCl) 481 
Superdex 200 column (GE Healthcare). Fractions containing the purified filaggrin were collected and 482 
analyzed by SDS-PAGE. Identical purification from cells without the expression plasmid were processed 483 
in parallel as a control. In both cases the same fractions from gel filtration column were collected. All 484 
experiments were performed in parallel using control SUMO protein. 485 
 486 
Filaggrin genotyping. The FLG mutations R501X and 2282del4 were genotyped using Taqman allelic 487 
discrimination assays (Life Technologies), as previously described(3). R501X was screened using forward 488 
primer 5’ CAC TGG AGG AAG ACA AGG ATC G 3’, reverse primer 5’ CCC TCT TGG GAC GCT GAA 3’ and the 489 
probes VIC-CAC GAG ACA GCT C  and 6-FAM-CAT GAG ACA GCT CC. 2282del4 was screened using 490 
forward primer 5’ CCA CTG ACA GTG AGG GAC ATT CA 3’, reverse primer 5’ GGT GGC TCT GCT GAT GGT 491 
GA 3’ and the probes 6-FAM- CAC AGT CAG TGT CAG GCC ATG GAC A and VIC-AGA CAC ACA GTG TCA 492 
GGC CAT GGA CA alleles. Assays were performed in 384-well plates with each reaction comprising of 493 
20ng DNA, 2.5 µl Universal PCR master mix and 0.125 µl 40X assay mix in a final reaction volume of 6 µl. 494 
Assays were run on an Applied Biosystems 7900HT Fast Real-Time PCR system under the following 495 
conditions:  1 cycle at 50°C for 2 minutes followed by 1 cycle at 95°C for 10 minutes then 40 cycles of 496 
95°C 15 sec; 60°C 1 minute. Samples heterozygous for the 2282del4 mutation were also confirmed by 497 
Sanger sequencing using the published primers RPT1P7 (5' – AAT AGG TCT GGA CAC TCA GGT - 3') and 498 
RPT2P1 (5' – GGG AGG ACT CAG ACT GTT T - 3') (84). PCR conditions were 94°C for 5 min; 35 cycles of 499 
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94°C for 40 s, 57°C for 1 min, 72°C for 2 min; final extension step at 72°C for 7 min. PCR clean up and 500 
sequencing was performed by Source Bioscience plc. 501 
 502 
Statistics. Cohort of healthy donors and atopic dermatitis patients investigated for CD1a-reactive HDM-503 
specific responses were analyzed using the one-tailed unpaired and paired t test, Chi-squared and 504 
Pearson correlation. All other polyclonal T-cells responses were analyzed using the unpaired t test. The 505 
number of biological replicates for each data point is included in the figure legends. Statistical analyses 506 
were performed using Prism 6 (GraphPad software Inc.) 507 
  508 
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Figure legends 781 
Figure 1. Circulating CD1a-reactive house dust mite-responsive T cells produce IFN, GM-CSF and IL-13.  782 
T cells were isolated by CD3 MACS beads from donor PBMC (R9500) and incubated overnight with CD1a-783 
transfected K562 (CD1a) or untransfected K562 (EV) cells pulsed with HDM extract.  IFN-γ (A), GM-CSF 784 
(B, left) and IL-13 (B, right) production were measured by ELISpot in the absence or presence of anti-785 
CD1a antibody (C) and at different HDM concentrations (D).  CD1a-expressing K562 (E, left), in vitro 786 
derived mDC (E, middle) or LC-like cells (E, right) were pulsed with HDM extract overnight and incubated 787 
with autologous peripheral blood T cells from donor R2.  IFN production was measured by ELISpot in 788 
the presence or absence of anti-CD1a antibody. Data representative of at least three donors for each 789 
experiment are shown.  Bars represent standard error. * P<0.05; ** P<0.01; ***P<0.001;****P<0.0001,  790 
t test. 791 
 792 
Figure 2. HDM-responsive CD1a-reactive T cells are enriched in blood and skin of atopic dermatitis 793 
patients.  (A,B) T cells derived from the peripheral blood of healthy controls (HC), patients with atopic 794 
dermatitis (AD) or from cord blood were incubated with CD1a-transfected K562 or untransfected K562 795 
cells in the presence or absence of HDM extract. IFN (A) and IL-13 (B) production were measured by 796 
ELISpot and expressed as percentage of responding T cells (A n=30 HC, 24 AD, 10 cord blood; B n=20 HC, 797 
17 AD, 10 cord blood). Auto-reactive is the response to CD1a-K562 in the absence of HDM. (C) Skin 798 
blister T cells from donor R229 were incubated with CD1a-transfected K562 or untransfected K562 cells 799 
in the presence or absence of HDM extract.  IFN (C, left), GM-CSF (C, middle) and IL-13 (C, right) 800 
production were measured by ELISpot.  Data are representative of at least three separate donors for 801 
each experiment.  (D) Example of skin suction blister raised after 60 minutes of 200mmHg negative 802 
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pressure. (E) Skin blister T cells were isolated from unchallenged skin of healthy controls (n=5) or 803 
patients with atopic dermatitis (n=4) and incubated with CD1a-transfected or untransfected K562 cells in 804 
the presence or absence of HDM extract.  IFN production was measured by ELISpot and expressed as 805 
percentage of CD1a-reactive T cells. Bars represent standard error. * P<0.05; ** P<0.01; 806 
***P<0.001;****P<0.0001, t test . 807 
 808 
Figure 3. HDM-responsive CD1a-reactive T cells infiltrate skin after HDM challenge. Skin blister T cells 809 
were isolated from donor R4 24 hours after HDM skin challenge, expanded and incubated with CD1a-810 
transfected or untransfected K562 cells in the presence or absence of HDM extract.  IFN (A, left), GM-811 
CSF (A, middle) and IL-13 (A, right) production by donor R4 cells were measured by ELISpot.  The data 812 
are representative of at least three separate donors for each experiment.  (B, left panel) Overall 813 
frequencies of HDM-responsive CD1a-reactive IFN-producing T cells infiltrating human skin after saline 814 
or HDM skin challenge were compared between healthy controls (n=4) and atopic dermatitis patients 815 
(n=8). Auto-reactive refers to responses to unpulsed K562-CD1a cells. (B, right panel) Skin blister cells 816 
derived from HDM-challenged or unchallenged skin were incubated with live attenuated varicella zoster 817 
virus and IFN production was measured by ELISpot.  (C) Concentrations of type 2 cytokines were 818 
measured in skin blister fluid by multiplex bead array after saline (nil) or HDM skin challenge in healthy 819 
controls (HC, n=8) or atopic (n=16) individuals. Bars represent standard error. * P<0.05; ** P<0.01; 820 
***P<0.001;****P<0.0001, t test. 821 
 822 
Figure 4. HDM extract contains PLA2 activity in vivo and in vitro. (A) T cells were isolated by CD3 MACS 823 
beads from healthy donor PBMC and incubated overnight with CD1a-transfected K562 (CD1a) or 824 
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untransfected K562 (EV) cells pulsed with HDM total extract, aqueous protein phase or lipid phase.  IFN-825 
γ production was measured by ELISpot (A). PLA2 activity in saline or HDM challenged skin blister fluid 826 
was detected by measuring free thiol release in the presence of the diheptanoyl thio-PC substrate in the 827 
absence (B) or presence (C) of 10μM of the PLA2 inhibitor manoalide.  (D) PLA2 activity in HDM extract 828 
in vitro was detected by measuring free thiol release in the presence of the diheptanoyl thio-PC 829 
substrate and manoalide and after heat inactivation (HDMhi). Data are representative of at least three 830 
separate experiments. Bars represent standard error. * P<0.05; ** P<0.01; ***P<0.001;****P<0.0001, t 831 
test. 832 
 833 
Figure 5.  HDM-derived PLA2 generates neolipid antigens for presentation by CD1a to blood and skin T 834 
cells.  T cells were isolated by CD3 MACS beads from healthy donor PBMC and incubated overnight with 835 
CD1a-transfected K562 (CD1a) or untransfected K562 (EV) cells pulsed with HDM total extract.  IFN-γ 836 
production was measured by ELISpot after HDM heat inactivation (hiHDM) (A, left) or overnight 837 
incubation with a dose titration of the PLA2 inhibitor manoalide (A, right).  Skin blister T cells were 838 
isolated 24 hours after HDM skin challenge, expanded and incubated with CD1a-transfected or 839 
untransfected K562 cells in the presence or absence of HDM extract that had been heat inactivated or 840 
incubated with manoalide.  IFN (B, left) and GM-CSF (B, right) production were measured by ELISpot.  841 
(C) Skin blister T cells were isolated 24 hours after HDM skin challenge, expanded and incubated with 842 
CD1a-transfected or untransfected K562 cells in the presence or absence of HDM extract or 1g/ml 843 
purified bee venom PLA2.  IFN production was measured by ELISpot.  Data are representative of at least 844 
three separate experiments. Bars represent standard error. * P<0.05; ** P<0.01; 845 
***P<0.001;****P<0.0001, t test. 846 
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 847 
Figure 6. Filaggrin inhibits HDM PLA2 activity and inhibits responses of HDM-responsive CD1a-reactive 848 
T cells isolated from blood and skin.  (A) PLA2 activity in HDM extract in vitro was detected by 849 
measuring free thiol release in the presence of the diheptanoyl thio-PC substrate, 10μM of the PLA2 850 
inhibitor manoalide and 1g/ml human recombinant filaggrin.  (B) PLA2 activity in HDM challenged skin 851 
blister fluid was detected by measuring free thiol release diheptanoyl thio-PC substrate in the absence 852 
or presence of filaggrin.  (C) T cells were isolated by CD3 MACS beads from healthy donor PBMC and 853 
incubated overnight with CD1a-transfected K562 or untransfected K562 cells pulsed with HDM total 854 
extract.  GM-CSF, IL-13 and IFN production were measured by ELISpot in the presence or absence of 855 
filaggrin.  (D) Skin blister T cells were isolated 24 hours after HDM skin challenge and incubated with 856 
CD1a-transfected or untransfected K562 cells in the presence or absence of HDM extract, filaggrin or 857 
anti-CD1a antibody. Data are representative of at least three separate experiments. Bars represent 858 
standard error. * P<0.05; ** P<0.01; ***P<0.001;****P<0.0001, t test. 859 
